Peucedanum japonicum Thunberg root extract inhibits atopic dermatitis-like skin symptoms
Main Article Content
Keywords
Peucedanum japonicum Thunberg root extract, atopic dermatitis-like skin symptoms, inflammation, NF-κB, therapeutic agent
Abstract
Peucedanum japonicum Thunberg is a perennial herbaceous plant of the genus Peucedanum that belongs to the Apiaceae family and is effective in improving inflammation, gout, and dizziness. However, the skin pruritus improvement effect and mechanism of action of Peucedanum japonicum Thunberg root extract (PJRE) have not yet been reported. We investigated the effects of PJRE on the regulation of pruritus and inflammatory responses in compound 48/80 (C48/80)-treated mice, phorbol 12-myristate 13-acetate (PMA)/A23187-induced human skin mast cells, and LPS-stimulated mouse macrophages. PJRE administration significantly inhibited scratching behavior, skin inflammatory cells, and mast cell infiltration in mice increased by C48/80. PJRE treatment also reduced the PMA/A23187-activated secretion of histamine, inflammatory cytokines, and interleukins via NF-κB activation in HMC-1 cells. PJRE treatment reduced LPS-stimulated secretion of inflammatory cytokines and expression of iNOS and COX-2 through phosphorylation of NF-κB, Akt, ERK1/2, and p38 MAPK in Raw 264.7 cells. PJRE treatment increases HO-1 expression in a concentration-dependent manner via NRF2 nuclear translocation. These results suggest that PJRE has therapeutic potential for alleviating atopic dermatitis-like skin symptoms, which is likely mediated by NF-κB as a transcription factor and Akt, ERK1/2, and p38 MAPK as upstream signaling molecules.
References
2 Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. Int J Mol Sci. 2020;21(8):2867. 10.3390/ijms21082867
3 Chong AC, Visitsunthorn K, Ong PY. Genetic/environmental contributions and immune dysregulation in children with atopic dermatitis. J Asthma Allergy. 2022;15:1681–700. 10.2147/JAA.S293900
4 Kim JE, Kim JS, Cho DH, Park HJ. Molecular mechanisms of cutaneous inflammatory disorder: Atopic dermatitis. Int J Mol Sci. 2016;17(8):1234. 10.3390/ijms17081234
5 Cetinarslan T, Kumper L, Folster-Holst R. The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update. Front Mol Biosci. 2023;10:1159404. 10.3389/fmolb.2023.1159404
6 Li L, Li ZE, Mo YL, Li WY, Li HJ, Yan GH, et al. Molecular and cellular pruritus mechanisms in the host skin. Exp Mol Pathol. 2024;136:104889. 10.1016/j.yexmp.2024.104889
7 Humeau M, Boniface K, Bodet C. Cytokine-mediated crosstalk between keratinocytes and T cells in atopic dermatitis. Front Immunol. 2022;13:801579. 10.3389/fimmu.2022.801579
8 Aschoff R, Lang A, Koch E. Effects of intermittent treatment with topical corticosteroids and calcineurin inhibitors on epidermal and dermal thickness using optical coherence tomography and ultrasound. Skin Pharmacol Physiol. 2022;35(1):41–50. 10.1159/000518214
9 Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B, et al. Systemic immunomodulatory treatments for atopic dermatitis: Update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022;158(5): 523–32. 10.1001/jamadermatol.2022.0455
10 Drucker AM, Lam M, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN, et al. Systemic immunomodulatory treatments for atopic dermatitis: Living systematic review and network meta-analysis update. JAMA Dermatol. 2024;160(9):936–44. 10.1001/jamadermatol.2024.2192
11 Filipiuc SI, Neagu AN, Uritu CM, Tamba BI, Filipiuc LE, Tudorancea IM, et al. The skin and natural cannabinoids-topical and transdermal applications. Pharmaceuticals (Basel). 2023;16(7):1049. 10.3390/ph16071049
12 Kwon CY, Lee B, Kim S, Lee J, Park M, Kim N. Effectiveness and safety of herbal medicine for atopic dermatitis: An overview of systematic reviews. Evid Based Complement Alternat Med. 2020;2020:4140692. 10.1155/2020/4140692
13 Chun JM, Lee AR, Kim HS, Lee AY, Gu GJ, Moon BC, et al. Peucedanum japonicum extract attenuates allergic airway inflammation by inhibiting Th2 cell activation and production of pro-inflammatory mediators. J Ethnopharmacol. 2018;211:78–88. 10.1016/j.jep.2017.09.006
14 Chun JM, Lee AY, Kim JS, Choi G, Kim SH. Protective effects of Peucedanum japonicum extract against osteoarthritis in an animal model using a combined systems approach for compound-target prediction. Nutrients. 2018;10(6):754. 10.3390/nu10060754
15 Kang WS, Choi H, Lee KH, Kim E, Kim KJ, Kim JS, et al. Peucedanum japonicum Thunberg and its active components mitigate oxidative stress, inflammation and apoptosis after urban particulate matter-induced ocular surface damage. Antioxidants (Basel). 2021;10(11):1717. 10.3390/antiox10111717
16 Gil TY, Jin BR, Lee JH, An HJ. In vitro and in vivo experimental investigation of anti-inflammatory effects of Peucedanum japonicum aqueous extract by suppressing the LPS-induced NF-[Formula: see text]B/MAPK JNK Pathways. Am J Chin Med. 2022;50(8):2153–69. 10.1142/S0192415X22500926
17 Hwang D, Ryu HW, Park JW, Kim JH, Kim DY, Oh JH, et al. Effects of 3’-isovaleryl-4’-senecioylkhellactone from Peucedanum japonicum Thunberg on PMA-stimulated inflammatory response in A549 human lung epithelial cells. J Microbiol Biotechnol. 2022;32(1):81–90. 10.4014/jmb.2107.07001
18 Gil TY, Jin BR, An HJ. Peucedanum japonicum Thunberg alleviates atopic dermatitis-like inflammation via STAT/MAPK signaling pathways in vivo and in vitro. Mol Immunol. 2022;144:106–16. 10.1016/j.molimm.2022.02.003
19 Park JH, Kim JH, Shin JY, Kang ES, Cho BO. Anti-inflammatory effects of Peucedanum japonicum Thunberg leaves extract in lipopolysaccharide-stimulated RAW264.7 cells. J Ethnopharmacol. 2023;309:116362. 10.1016/j.jep.2023.116362
20 Park JH, Kim JH, Jang SI, Cho BO. Anti-inflammatory of disenecionyl cis-khellactone in LPS-stimulated RAW264.7 cells and the its inhibitory activity on soluble epoxide hydrolase. Heliyon. 2023;9(10):e21032. 10.1016/j.heliyon.2023.e21032
21 Gilhar A, Reich K, Keren A, Kabashima K, Steinhoff M, Paus R. Mouse models of atopic dermatitis: A critical reappraisal. Exp Dermatol. 2021;30(3):319–36. 10.1111/exd.14270
22 Riedl R, Kuhn A, Hupfer Y, Hebecker B, Peltner LK, Jordan PM, et al. Characterization of different inflammatory skin conditions in a mouse model of DNCB-induced atopic dermatitis. Inflammation. 2024;47(2):771–88. 10.1007/s10753-023-01943-x
23 Zheng J, Gu A, Kong L, Lu W, Xia J, Hu H, et al. Cimifugin relieves histamine-independent itch in atopic dermatitis via targeting the CQ receptor MrgprA3. ACS Omega. 2024;9(6):7239–48. 10.1021/acsomega.3c09697